Transdominant Rev and Protease Mutant Proteins of HIV/SIV as Potential Antiviral Agents In vitro and In vivo.
Abstract
The major goal of this contract is to use gene therapy to target essential genes of HIV/SIV in order to inhibit virus expression. Transdominant mutants of the rev and protease genes were to be constructed, assayed for their in vitro inhibitory activity, optimized for expression in appropriate retrovirus vectors, and evaluated in an in vivo model, i.e., the SCID-Hu-PBL system. We have so far constructed mutants of HIV-1 rev and HIV-2 protease, and demonstrated that one of the rev mutants indeed has a transdominant phenotype. Our plan for year two will be to continue these studies, to develop in parallel the infection of SCID mice using molecularly cloned HIV-1 and HIV-2 under study, and to incorporate antisense expression vectors directed at the RRE to inhibit Rev activity. RA 1; HIV/SIV; AIDS; Transdominant mutants; Rev; Protease; Retrovirus vector; SCID-Hu Mice models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 03, 1991
- Accession Number
- ADA251525
Entities
People
- Flossie Wong-staal
Organizations
- University of California, San Diego